Podcasts about Igi

W dzisiejszym magazynie sportowym o historycznym zwycięstwie Igi Świątek na Wimbledonie. Tenisistka zapisuje się w historii jako pierwsza Polka z wielkoszlemowym tytułem na londyńskich kortach.

Enzo, Igi e Stefano hanno il piacere di ospitare Giorgio Tavecchio, un passato in NFL ed Elf come Kicker a Oakland, Atlanta e altro, per parlarci della sua esperienza, del ruolo del Kicker, della difficoltà di un ruolo così particolare. Tante spiegazioni tecniche per capire meglio il ruolo, una spiegazione della parte psicologica del ruolo. Esperienze ed aneddoti della NFL dalla sua diretta esperienza.In puntata anche il nostro amico Davide Gabino.Una puntata eccezzionale con un ospite di altissimo livello!

W dzisiejszym magazynie sportowym m.in. pierwszy finał Igi Świątek w turnieju na kortach trawiastych, sukcesy polskich siatkarzy i siatkarek w Lidze Narodów, Polak zawodowym mistrzem świata w boksie.

Gośćmi Edyty Kowalczyk i Łukasza Kadziewicza będą: Sebastian Świderski, Radosław Majdan, Michał Zawacki, Bartek Ignacik i Aaron Cel. Porozmawiamy o zbliżających się mistrzostwach Europy w piłce nożnej kobiet, o świetnych występach naszych siatkarek i siatkarzy w Lidze Narodów, o ostatnim sprawdzianie Igi Świątek przed Wimbledonem oraz o tryumfie Legii Warszawa, ale nie tej piłkarskiej, a koszykarskiej.

Mimo wszystko, trzeba podkreślić, że oba tegoroczne turnieje Wielkiego Szlema to są naprawdę dobre starty Igi Świątek - zwraca uwagę redaktor naczelny portalu Historia Tenisa. 

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates discuss Victoria's recent trip to Paris as a guest of Japanese watchmaker Credor to celebrate the brand's update on a classic Gérald Genta timepiece from 1979. Next, the pair gear up for JCK Las Vegas by highlighting some of the exciting events on their show agenda, from Rob moderating an expert panel on cybercrime and security to Victoria reporting on emerging jewelry trends from the show floor. Other highpoints on the lineup include a keynote speech from Disney's former head of innovation and live performances by Jason Derulo and Snoop Dogg. Sponsored by IGI: igi.org/education

Grandi rinnovi in casa Niners, John Lynch e la proprietà mettono al sicuro 3 pilastri della franchigia: Brock Purdy, George Kittle e Fred Warner!Enzo, Igi e Stefano nel parlano in questo episodio.

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates talk with Marc Bridge, CEO and founder of online jewelry platform At Present. A fifth-generation scion of the Ben Bridge family, Marc describes a life in the industry that began with cleaning jewelry cases as soon as he was tall enough to reach them, included a memorable cross-country trip to deliver homemade cookies to Warren Buffett, and spanned decades as a problem solver for the family firm. He urges the industry to sharpen its storytelling skills in order to deepen consumers' appreciation for gems and explains his role as matchmaker through At Present, connecting jewelry lovers who crave unique pieces with the artisans who create them. Presenting sponsor: IGI (igi.org/education) Sponsor: Nivoda (nivoda.com)

W dzisiejszym magazynie sportowym m.in. o porażce Igi Świątek, która ma katastrofalne skutki dla rankingu WTA! Polka nie będzie już drugą rakietą świata i spadnie na pozycję numer cztery.

W audycji również rzut oka na nieudany występ Igi Świątek w turnieju WTA w Rzymie.

Puntata di analisi del draft 2025 dei San Francisco 49ers.In studio Enzo, Igi e Stefano. Siamo lieti di aver pututo ospitare, anche se da remoto, il fine conoscitore NCAA Oleg Bogdea, penna e voce di: La strada verso il draft, Podcast verso/dopo il draft, Scusate il Collage Football.Su tutte le piattaforme podcast oltre la Live Video di YouTube.

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates explore the ramifications of the staggering rise in gold prices and share a strategy jewelers can use to offer gold at more palatable prices. (Hint: Think vintage.) Next, the conversation turns to tariffs. What's ahead? What's the best way to navigate it? Jewelers learned to pivot during the pandemic, and that agility will help them weather today's volatile times, Rob and Victoria predict. They wrap up the conversation with a preview of what to expect when JCK Las Vegas kicks off in June. Presenting sponsor: IGI (igi.org/education) Sponsor: Nivoda (nivoda.com)

W dzisiejszym magazynie sportowym : finał pucharu Polski w piłce nożnej, ostatnia kolejka australijskiej piłkarskiej A-League oraz dramat Igi Świątek na turnieju w Madrycie...

In this week's episode, JCK editor-in-chief Victoria Gomelsky and news director Rob Bates Victoria discuss highlights from Watches and Wonders, including a Bremont relaunch, new Bulgari pieces, and Rolex's first new collection in 13 years. “Rolex has really thrown down the gauntlet,” with its new Dynapulse escapement, Victoria reports. Next, the pair analyze the effect the U.S. administration's initial tariff announcements had on the jewelry industry (confusion and worry) and offer some perspective on what may lie ahead in a time of rapid change and continuing uncertainty. Presenting sponsor: IGI (igi.org/education) Sponsor: Nivoda (nivoda.com)

Gośćmi Edyty Kowalczyk i Łukasza Kadziewicza w "Misji Sport" będą: Tomasz Wolfke, Łukasz Olkowicz, Wojsław Rysiewski, Tomasz Mańko i Bartosz Huzarski. Wśród tematów m.in. niemoc Igi Świątek w meczach z Jeleną Ostapenko, walka o mistrza Ekstraklasy oraz bój o utrzymanie, a także zbliżająca się gala KSW w Gliwicach. 

W dzisiejszym magazynie sportowym: wygrana Legi w jaskini lwa 2:1 dla Warszawiaków z Chelsea London, Sydney FC odpada w półfinale azjatyckiej ligi mistrzów oraz czarna seria Igi Świątek w konfrontacji z Jeleną Ostapenką.

Gośćmi Aldony Marciniak i Łukasza Kadziewicza będą: Dawid Celt, Andrzej Grzebyk, Jarosław Koliński, Radosław Kietliński i Kamil Wolnicki. Porozmawiamy o weekendowych zmaganiach w Billie Jean King Cup oraz o powrocie Igi Świątek do gry. Zaczyna się przecież granie na kortach ziemnych. Następnie przejdziemy do zbliżającej się gali XTB KSW 105. W walce wieczoru zmierzą się Andrzej Grzebyk i Adrian Bartosiński, a pierwszy z nich będzie w naszym studio. Zastanowimy się także nad tym, czy coś zaskakującego może się jeszcze wydarzyć w rewanżach Ligi Mistrzów, a także o tym, jakiego czwartku spodziewać się w wykonaniu polskich drużyn w Lidze Konferencji Europy.

W dzisiejszym magazynie sportowym: dwie niespodzianki w turnieju tenisowym w Miami-wygrana Magdy Linette z Coco Gauff i przegrana Igi Świątek z zajmującą 140 miejsce 19-łatką z Filipin; polska reprezentacja narodowa w piłce nożnej z kompletem punktów w eliminacjach do mistrzostw świata oraz zwycięstwo Socceroos nad drużyną Chin 2:0 w eliminacyjnym meczu do mistrzostw świata...

Gośćmi Aldony Marciniak i Łukasza Kadziewicza w kolejnym odcinku "Misji Sport" będą Bartek Ignacik, Mateusz Leleń, Kamil Wolnicki i Łukasz Olkowicz. A porozmawiamy o tym, co przetacza się właśnie przez polskie skoki, o echach turnieju w Miami i o tym, jak przebiega współpraca Igi Świątek z Wimem Fisette a także o sytuacji w polskiej Ekstraklasie - czy ktoś jeszcze będzie w stanie zagrozić piłkarzom Marka Papszuna?

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates recap highlights from NYC Jewelry Week, including takeaways from The Plumb Club's Symposium '25 that leaders everywhere can apply to help their businesses succeed. Rob brings listeners up to speed on how the ever-changing tariff news could impact the jewelry industry and shares emerging trends from the diamond market. Finally, Victoria discusses the most-talked-about rumors and reports from the watch world, including acquisitions, major management shifts shaking up the top players, and buzz about a potential new line from Rolex. Sponsored by IGI: igi.org/education

On this week's episode, JCK editor-in-chief Victoria Gomelsky and news director Rob Bates discuss highlights from the colored gem shows in Tucson, where designers were buzzing over Guatemalan jade. Rob updates listeners on big news from De Beers, which sealed a 10-year deal with Botswana and saw its value written down significantly. In other news, one of Signet's largest shareholders has called for a sale of the company. Rob offers insights into the factors driving these headline-making stories. Finally, Victoria reports on the state of the Swiss watch industry as Audemars Piguet marks its 150th anniversary. Sponsored by IGI: igi.org/education

W dzisiejszym magazynie sportowym: awans Igi Świątek do trzeciej rundy tenisowego turnieju Indian Wells, polski napastnik Patryk Klimala zapewnił zwycięstwo Sydney FC w ćwierć finałach azjatyckiej piłkarskiej Ligi Mistrzów oraz polscy sportowcy zdobywają medale w halowych mistrzostwach Europy w lekkiej atletyce...

Victoria Gomelsky and Rob Bates interview John Greene, president and CEO of Lux Bond & Green, a fifth-generation family-owned jewelry store based in Connecticut. John, winner of the 2025 Gem Award for Lifetime Achievement, recounts the story of a 127-year retailing tradition in his family. He also offers insights into noteworthy trends he's seeing on the sales floor. Sponsored by IGI: igi.org

Paweł Wąsek będzie gościem Aldony Marciniak i Sebastiana Parfjanowicza w "Misji Sport" tuż przed mistrzostwami świata w Trondheim. Z naszym najlepszym skoczkiem w tym sezonie porozmawiamy o emocjach towarzyszących mu przed startem najważniejszej imprezy tego sezonu, o tym, jak to jest być liderem kadry i co poczuł, kiedy dowiedział się, że na mistrzostwa nie poleci legenda polskich skoków, Kamil Stoch. Ale to nie wszystko o skokach. Wśród zaproszonych gości są także Sebastian Szczęsny i Kamil Wolnicki, z którymi przeanalizujemy możliwe scenariusze przed Trondheim i zastanowimy się, jaki wpływ na atmosferę w drużynie może mieć zamieszanie z Alexandrem Stoecklem. Ale zanim o skokach, to w studio gościć będziemy Dawida Celta, cenionego eksperta, komentatora i trenera tenisa. Tematem początek sezonu w wykonaniu Igi Świątek.

W audycji również analiza sytuacji w kadrze polskich skoczków przed mistrzostwami świata w Trondheim i ocena występu Igi Świątek w Dosze.

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates discuss LVMH's recent annual Watch Week in New York City. Highlights include Tiffany's dazzling 13-foot Bird on a Rock sculpture, cutting-edge clocks in the shape of cars and grenades from L'Epée, and a mini miracle—a tiny mechanical Bulgari Serpenti watch. Next, Victoria and Rob share some perspective on recent reports about trouble at LVMH and downturns in the Swiss watch market. Finally, the pair honor a jeweler with a heart of gold, the late Harvey Rovinsky of Bernie Robbins. Sponsored by IGI: igi.org

JCK editor-in-chief Victoria Gomelsky and news director Rob Bates interview our first-ever father-daughter guest duo, Richard “Dick” Hughes and Billie Hughes, co-founders of Lotus Gemology, a full-service colored gemstone testing lab based in Bangkok. The pair give listeners an insider's guide to the complex world of colored stones. Why is describing faceted color gemstones “pure hell”? (“It's like trying to describe the wind,” in Dick's words.) How do experts really detect treated stones? Bonus: Find out how you can learn more from these experts in Tucson. Sponsored by IGI: igi.org

Edyta Kowalczyk i Aldona Marciniak zapraszają na "Misję Sport". Razem z Dawidem Celtem podsumujemy sobie tegoroczne Australian Open. Aż półfinał, czy tylko półfinał Igi Świątek? W jakim miejscu jest dzisiaj Hubert Hurkacz? O to zapytamy naszego eksperta. Z Iwoną Niedźwiedź natomiast przeanalizujemy występ naszych piłkarzy ręcznych w mistrzostwach świata. Czy gra o 25. miejsce to dziś szczyt naszych możliwości? Po świetnych lotach Pawła Wąska w niedzielę, będzie też z nami Michał Korościel. Zbliżają się także mistrzostwa świata w narciarstwie klasycznym, a stamtąd od wielu lat przywoziliśmy medale w skokach narciarskich. Czy ten rok będzie pierwszym od 2009 roku, w którym nie zdobędziemy żadnego? Ale zaczniemy od smutnej wiadomości. Z Kamilem Drągiem pożegnamy i powspominamy wieloletniego dziennikarza i honorowego redaktora naczelnego, Macieja Petruczenkę.

I San Francisco 49ers hanno già cominciato a pensare alla stagione 2025 mentre la NFL gioca i playoff ! Enzo e Igi hanno il piacere di ospitare Alessandro Redaelli del Beer Corner, da anni pub che trasmette le partite per i Faithful ! Parleremo dei playoff in corso e delle mosse per il futuro Rosso e Oro!

Hala Abdallah is a Saudi Arabian content creator, entrepreneur, and global influencer. A graduate of OTIS College of Art and Design in Los Angeles. And jewelry design from IGI she combines her passion for art, design, and fashion through her brand, OFA. Known for her striking style and collaborations with luxury brands, Hala is redefining influencer culture in the Middle East. An adventurous spirit, she's a horse rider, she's a scuba diver, and world traveler who draws inspiration from her own life.  On this episode, Mo and Hala explore wide range of topics, the power of action over perfection, emphasizing how taking risks and embracing failure drives personal and professional growth. They discuss starting small, iterating, and overcoming the fear of failure, highlighting strategies for cultivating action, balancing preparation with bold decisions, and building confidence to take the first step. 00:00 Intros02:45 Background & Early Life07:30 Finding Passion Through Curiosity12:15 Breaking Barriers18:40 The Role of Fear in Personal Growth23:10 Interpretation & Influence30:05 Transformative Moments in Adulthood35:50 Cultural Narratives40:20 Building Bridges Through Storytelling45:15 Challenges Faced as a Creative50:00 Overcoming Doubt & Embracing Purpose55:40 Listening to Your Inner Voices1:01:20 Spirituality & the Power of Prayer1:05:35 Connection & Community1:10:10 Hala's Favorite Creative Mediums1:15:50 Navigating Life's Transitions1:20:30 The Role of Mentors1:25:45 Childhood Dreams1:30:15 Moments of Self-Discovery1:35:00 Overcoming Loss1:40:15 Childhood Dreams & Telepathic Connections1:47:20 Self-Reflection1:54:30 Designing a Life of Gratitude

Aldona Marciniak i Sebastian Parfjanowicz zapraszają na Misję Sport! W programie o świetnym turnieju w wykonaniu Igi Świątek. Czy któraś z zawodniczek będzie w stanie zatrzymać polską tenisistkę? Czy w końcu zobaczymy w finale dwie najlepsze zawodniczki touru - czyli Igę Świątek i Arynę Sabalenkę? O to zapytamy Michała Dembka, trenera i eksperta tenisowego. Będzie też o najsłabszym występie reprezentacji Polski w historii mistrzostw Świata. Co nie zagrało? Czy przed tą drużyną jest jakaś przyszłość? Czy Marcin Lijewski to odpowiednia osoba na stanowisku trenera kadry? O tym porozmawiamy z komentatorem i ek

Victoria Gomelsky and Rob Bates discuss recent holiday sales results and weigh in on what 2025 may bring for jewelers as a new administration takes office, tariffs loom on the horizon, and gold prices remain high. Also discussed is the latest news from De Beers after a less-than-banner year, Rob's upcoming mystery novel (the final installment of his Diamond District series), and how factors such as Pantone's Color of the Year and the Year of the Snake may—or may not—impact jewelry design. Sponsored by IGI: igi.org

Dense fog alert: Zero visibility in parts of Delhi NCR as AQI drops; Flight departures hit at IGI, Pune woman murdered by colleague at office parking lot; viral video shows mute onlookers, California wildfires: ‘Apocalyptic' fires continue, over 4,000 structures gone; toll likely to rise, All We Imagine As Light wins big at NYFCC awards, Rohit Sharma's post-Champions Trophy retirement plan mooted by his ex-IPL captain

W podsumowaniu roku Sport in brief: Igrzyska olimpijskie w Paryżu EURO 2024 Trudny rok Igi Świątek Chcesz mieć najważniejsze wiadomości o gospodarce, nowych technologiach, sporcie, marketingu i zmianach na świecie zebrane w jednym miejscu? Zasubskrybuj kanał Jarosław Kuźniar in Brief ► https://bit.ly/J-Kuzniar-inBrief Uwielbiasz podcasty? Słuchać, tworzyć, produkować, wszystko naraz? Zapisz się na newsletter Voice House o świecie podcastingu ► https://bit.ly/newsletterVoiceHouse Masz pomysł na rozmowę? Napisz ► office@voicehouse.co

W dzisiejszym magazynie sportowym: awans polskich drużyn piłkarskich do dalszej fazy rozgrywek Ligi Konferencji Europy, sensacyjne wyniki w australijskiej piłkarskiej A-League, oraz trzy nagrody dla Igi Świątek na zakończenie sezonu tenisowego...

Streak negativa interrotta con San Francisco, ne parliamo insime a Igi si Italian Red&Gold

W najnowszym odcinku Sport in Brief: Wim Fisette nowym trenerem Igi Świątek Jeremy Sochan zostaje w San Antonio Spurs Robert Lewandowski liderem klasyfikacji strzelców Chcesz mieć najważniejsze wiadomości o gospodarce, nowych technologiach, sporcie, marketingu i zmianach na świecie zebrane w jednym miejscu? Zasubskrybuj kanał Jarosław Kuźniar in Brief ► https://bit.ly/J-Kuzniar-inBrief Uwielbiasz podcasty? Słuchać, tworzyć, produkować, wszystko naraz? Zapisz się na newsletter Voice House o świecie podcastingu ► https://bit.ly/newsletterVoiceHouse Masz pomysł na rozmowę? Napisz ► office@voicehouse.co

W dzisiejszym magazynie sportowym: sensacyjne rozstanie Igi Świątek z trenerem, zaskakujące wygranie polskich drużyn w europejskich pucharach piłkarskich oraz wielki finał w Rugby League dla Penrith Panthers.

SZYBKO, SZYBKO ŻEBY ZDĄŻYĆ!!! Dziś z Patrykiem jako gościem, bo nie ma Igi. Wspominamy nasze czasy dziennikarzenia i to, co było w nich dobre (staramy się nie marudzić ;)). w CJG Patryk mówi o nowej Zeldzie, Dominik o Astro Bocie, a Tomek o komiksie O najntisach, miłości, kobiecości i młodości. Dziękujemy za wsparcie na patronite.pl/niezatapialni!

The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don't. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits.

Which trees would you keep if you had to narrow your collection down to three trees? What would you look to acquire if you lost all of your trees?South African bonsai grower Richard Wright has faced these and similar questions more than once since he started working with small trees, and he's found that the experience has given him great focus in life and in bonsai. Learn more about Rich:Bonsai Rich on IGI am Richard Wright (personal website)

Magazyn sportowy w opracowaniu Piotra Pokorskiego, w którym m.in. triumf Igi Świątek na Roland Garros w Paryżu. Ewa Swoboda zdobyła srebrny medal lekkoatletycznych mistrzostw Europy w Rzymie w biegu na 100 metrów. Dobry początek dla polskich piłkarzy ...

W dzisiejszym magazynie Piotr Pokorski omawia: wspaniały sukces Igi Świątek w Rzymie, znamy finalistów australisjskiej A-Leuge, przedostanią kolejkę polskiej ekstraklasy piłkarskiej, mistrzostwa Świata w hokeju na lodzie oraz wspaniałą postawę Polek w siatkarskiej lidze narodów.

Join NAFI: www.nafinet.org Podcast listeners can get a $10 discount to NAFI memberships by using Discount Code: POD49 This episode is sponsored by: Sporty's May is Learn to Fly Month at Sporty's. It's a four-week celebration of learning to fly designed to inspire and help new pilots achieve their aviation goals. In addition to savings on popular pilot gear, Sporty's Media Network will celebrate Learn to Fly Month with articles, videos, webinars and more.  Visit sportys.com/learntoflymonth for more information  ----------------------------------------------------------------------- Earn FAA Wings Credits for Listening: Click Here to take the Wings Quiz Mental health is a critical aspect of our overall well-being, and it is essential for pilots and others in aviation as well. Significant underreporting of mental health conditions is known to be widespread throughout the aviation industry. In this episode, we will review the signs and symptoms of mental illness and explore ways that pilots may self-report any mental health issues they may be experiencing. We will discuss how flight instructors can be alert to the signs and symptoms of mental illness, and we will explain how to remove the stigma that surrounds mental health issues. We will highlight reporting systems that are designed to maintain confidentiality while ensuring that individuals receive the necessary support while taking appropriate measures to ensure flight safety.   Dr. Victor Vogel is a board-certified and fellowship-trained medical oncologist specializing in breast cancer prevention and treatment. He obtained his medical degree from Temple University School of Medicine, completed his residency at Johns Hopkins Bayview Medical Center, and his fellowship in medical oncology at the Johns Hopkins Oncology Center. Dr. Vogel has also served as the National Vice President for Research at the American Cancer Society. A pilot since 1980, Dr. Vogel holds a CFII, AGI, and IGI. He has owned a Beech Sierra and for the past 15 years a Cirrus SR22. He has flown to 40 of the 50 states and serves as a FAASTeam Representative. He is a member of the IFR Magazine Editorial Board. In retirement, Dr. Vogel plans to become a full-time flight instructor and is the founder of Susquehanna STEM to the Skies, an educational foundation that will utilize a full-motion advanced aviation training device to introduce high school youth to aviation as a career opportunity.

Mystery novelist and JCK News Director Rob Bates returns to the show for a seventh time. The show begins with Paul analyzing whether the current diamond market softness is more cyclical or secular in nature. Next, Paul and Rob talk about how the retail segment of the trade is currently viewing lab-grown diamonds and whether a “pivot” back to natural diamonds is in the cards. The two then discuss what they got right and wrong about the evolution of LGD jewelry over the last decade. Next, Paul and Rob dissect a ruling by the U.K.'s Advertising Standards Agency pertaining to LGD producer Skydiamond and they share thoughts on news of for-profit gem-lab IGI reportedly considering a public offering. Finally, the two opine on the watch market and whether they would personally buy a Rolex.   Hosted by: Paul Zimnisky Guest: Rob Bates Guest plug: www.robbatesauthor.com More information on PZDA's State of the Diamond Market report: www.paulzimnisky.com/products   Show contact: paul@paulzimnisky.com or visit www.paulzimnisky.com.   Please note that the contents of this podcast includes anecdotes, observations and opinions. The information should not be considered investment or financial advice. Consult your investment professional before making any investment decisions. Please read full disclosure at: www.paulzimnisky.com.

Join NAFI: www.nafinet.org Podcast listeners can get a $10 discount to NAFI memberships by using Discount Code: POD49 This episode is sponsored by: Avemco Insurance Company Learn more about the NAFI CFI Insurance Plan ------------------------------------------------------------------- Discover the vital knowledge every pilot should possess regarding takeoff rejects. Through insightful explanations and practical examples, this video aims to equip both experienced aviators and aspiring pilots with the necessary skills to make informed decisions during critical moments before takeoff. Philip Mandel earned his Private in 1981 followed by his Instrument rating, Commercial cert, CFI, CFI-I, MEI, AGI, and IGI certs and rating. He has owned airplanes ranging from a C-150 to a Piper Apache and is currently the proud owner of his 10th aeroplane, a Thorp T-18 (no, he didn't build it). Phil is an active flight instructor based at Starks Twin Oaks Airpark, 7S3, Hillsboro OR. He was the FAASTeam Rep of the Year for the Portland, OR FSDO in 2020 and 2021.  

Professor Doudna was awarded the 2020 Nobel Prize in Chemistry with Professor Emmanuelle Charpentier for their pioneering work in CRISPR genome editing. The first genome editing therapy (Casgevy) was just FDA approved, only a decade after the CRISPR-Cas9 editing system discovery. But It's just the beginning of a much bigger impact story for medicine and life science.Ground Truths podcasts are now on Apple and Spotify. And if you prefer videos, they are posted on YouTubeTranscript with links to audio and relevant external linksEric Topol (00:06):This is Eric Topol with Ground Truths, and I'm really excited today to have with me Professor Jennifer Doudna, who heads up the Innovative Genomics Institute (IGI) at UC Berkeley, along with other academic appointments, and as everybody knows, was the Nobel laureate for her extraordinary discovery efforts with CRISPR genome editing. So welcome, Jennifer.Jennifer Doudna (00:31):Hello, Eric. Great to be here.Eric Topol (00:34):Well, you know we hadn't met before, but I felt like I know you so well because this is one of my favorite books, The Code Breaker. And Walter Isaacson did such a wonderful job to tell your story. What did you think of the book?My interview with Walter Isaacson on The Code Breaker, a book I highly recommendJennifer Doudna (00:48):I thought Walter did a great job. He's a good storyteller, and as you know from probably from reading it or maybe talking to others about it, he wrote a page turner. He actually really dug into the science and all the different aspects of it that I think created a great tale.Eric Topol (01:07):Yeah, I recommended highly. It was my favorite book when it came out a couple years ago, and it is a page turner. In fact, I just want to read one, there's so many quotes out of it, but in the early part of the book, he says, “the invention of CRISPR and the plague of Covid will hasten our transition to the third great revolution of modern times. These revolutions arose from the discovery beginning just over a century ago, of the three fundamental kernels of our existence, the atom, the bit, and the gene.” That kind of tells a big story just in one sentence, but I thought I'd start with the IGI, the institute that you have set up at Berkeley and what its overall goals are.Jennifer Doudna (01:58):Right. Well, let's just go back a few years maybe to the origins of this institute and my thinking around it, because in the early days of CRISPR, it was clear that we were really at a moment that was quite unique in the sense that there was a transformative technology. It was going to intersect with lots of other discoveries and technologies. And I work at a public institution and my question to myself was, how can I make sure that this powerful tool is first of all used responsibly and secondly, that it's used in a way that benefits as many people as possible, and it's a tall order, but clearly we needed to have some kind of a structure that would allow people to work together towards those goals. And that was really the mission behind the IGI, which was started as a partnership between UC Berkeley and UCSF and now actually includes UC Davis as well.The First FDA Approved Genome EditingEric Topol (02:57):I didn't realize that. That's terrific. Well, this is a pretty big time because 10 years or so, I guess starting to be 11 when you got this thing going, now we're starting to see, well, hundreds of patients have been treated and in December the FDA approved the first CRISPR therapy for sickle cell disease, Casgevy. Is that the way you say it?Jennifer Doudna (03:23):Casgevy, yeah.Eric Topol (03:24):That must have felt pretty good to see if you go from the molecules to the bench all the way now to actually treating diseases and getting approval, which is no easy task.Jennifer Doudna (03:39):Well, Eric, for me, I'm a biochemist and somebody who has always worked on the fundamentals of biology, and so it's really been extraordinary to see the pace at which the CRISPR technology has been adopted, and not just for fundamental research, but also for real applications. And Casgevy is sort of the crowning example of that so far, is that it's really a technology that we can already see how it's being used to, I think it's fair to say, effectively cure a genetic disease for the first time. Really amazing.Genome Editing is Not the Same as Gene TherapyEric Topol (04:17):Yeah. Now I want to get back to that. I know there's going to be refinements about that. And of course, there's beta thalassemia, so we've got two already, and our mutual friend Fyodor Urnov would say two down 5,000 to go. But I think before I get to the actual repair of the sickle cell defect molecular defect, I think one of the questions I think that people listeners may not know is the differentiation of genome editing with gene therapy. I mean, as you know, there was recently a gene therapy approval for something like $4.25 million for metachromatic leukodystrophy. So maybe you could give us kind of skinny on how these two fundamental therapies are different.Jennifer Doudna (05:07):Right. Well, it's a great question because the terminology sounds kind of the same, and so it could be confusing. Gene therapy goes back decades, I can remember gene therapy being discussed as an exciting new at the time, direction back when I was a graduate student. That was little while ago. And it refers to the idea that we can use a genetic approach for disease treatment or even for a cure. However, it fundamentally requires some mechanism of integrating new information into a genome. And traditionally that's been done using viruses, which are great at doing that. It's just that they do it wherever they want to do it, not necessarily where we want that information to go. And this is where CRISPR comes in. It's a technology allows precision in that kind of genetic manipulation. So it allows the scientist or the clinician to decide where to make a genetic change. And that gives us tremendous opportunity to do things with a kind of accuracy that hasn't been possible before.Eric Topol (06:12):Yeah, no question. That's just a footnote. My thesis in college at University of Virginia, 1975, I'm an old dog, was prospects for gene therapy in man. So it took a while, didn't it? But it's a lot better now with what you've been working on, you and your colleagues now and for the last decade for sure. Now, what I was really surprised about is it's not just of course, these hemoglobin disorders, but now already in phase two trials, you've got hereditary angioedema, which is a life-threatening condition, amyloidosis, cancer ex vivo, and also chronic urinary tract infections. And of course, there's six more others like autoimmune diseases like lupus and type 1 diabetes. So this is really blossoming. It's really extraordinary.Eric Topol (07:11):I mean, wow. So one of the questions I had about phages, because this is kind of going back to this original work and discovery, antimicrobial resistance is really a big problem and it's a global health crisis, and there's only two routes there coming up with new drugs, which has been slow and not really supported by the life science industry. And the other promising area is with phages. And I wonder, since this is an area you know so well, why haven't we put more, we're starting to see more trials in phages. Why haven't we doubled down or tripled down on this to help the antimicrobial resistance problem?Jennifer Doudna (08:00):Well, it's a really interesting area, and as you said, it's kind of one of those areas of science where I think there was interest a while ago and some effort was made for reasons that are not entirely clear to me, at least it fizzled out as a real focused field for a long time. But then more recently, people have realized that there's an opportunity here to take advantage of some natural biology in which viruses can infect and destroy microbes. Why aren't we taking better advantage of that for our own health purposes? So I personally am very excited about this area. I think there's a lot of fundamental work still to be done, but I think there's a tremendous opportunity there as well.CRISPR 2.0Eric Topol (08:48):Yeah, I sure think we need to invest in that. Now, getting back to this sickle cell story, which is so extraordinary. This is kind of a workaround plan of getting fetal hemoglobin built up, but what about actually repairing, getting to fixing the lesion, if you will?Eric Topol (09:11):Yeah. Is that needed?Jennifer Doudna (09:13):Well, maybe it's worth saying a little bit about how Casgevy works, and you alluded to this. It's not a direct cure. It's a mechanism that allows activation of a second protein called fetal hemoglobin that can suppress the effect of the sickle cell mutation. And it's great, and I think for patients, it offers a really interesting opportunity with their disease that hasn't been available in the past, but at the same time, it's not a true cure. And so the question is could we use a CRISPR type technology to actually make a correction to the genetic defect that directly causes the disease? And I think the answer is yes. The field isn't there quite yet. It's still relatively difficult to control the exact way that DNA editing is occurring, especially if we're doing it in vivo in the body. But boy, many people are working on this, as you probably know. And I really think that's on the horizon.Eric Topol (10:19):Yeah. Well, I think we want to get into the in vivo story as well because that, I think right now it's so complicated for a person to have to go through the procedure to get ultimately this treatment currently for sickle cell, whereas if you could do this in vivo and you could actually get the cure, that would be of the objective. Now, you published just earlier this month in PNAS a wonderful paper about the EDVs and the lipid nanoparticles that are ways that we could get to a better precision editing. These EDVs I guess if I have it right, enveloped virus-like particles. It could be different types, it could be extracellular vesicles or whatnot. But do you think that's going to be important? Because right now we're limited for delivery, we're limited to achieve the right kind of editing to do this highly precise. Is that a big step for the future?Jennifer Doudna (11:27):Really big. I think that's gating at the moment. Right now, as you mentioned, somebody that might want to get the drug Casgevy for sickle cell disease or thalassemia, they have to go through a bone marrow transplant to get it. And that means that it's very expensive. It's time consuming. It's obviously not pleasant to have to go through that. And so that automatically means that right now that therapy is quite restricted in the patients that it can benefit. But we imagine a day when you could get this type of therapy into the body with a one-time injection. Maybe someday it's a pill that could be taken where the gene editors target the right cells in the body. In diseases like that, it would be the stem cells in the bone marrow and carry out gene editing that can have a therapeutic benefit. And again, it's one of those ideas that sounds like science fiction, and yet already there's tremendous advance in that direction. And I think over the next, I don't know, I'm guessing 5 to 10 years we're going to see that coming online.Editing RNA, the Epigenome, and the MicrobiomeEric Topol (12:35):Yeah, I'm guessing just because there's so much work on the lipid nanoparticles to tweak them. And there's four different components that could easily be made so much better. And then all these virus-like proteins, I mean, it may happen even sooner. And it's really exciting. And I love that diagram in that paper. You have basically every organ of the body that isn't accessible now, potentially that would become accessible. And that's exciting because whatever blossoming we're seeing right now with these phase two trials ongoing, then you basically have no limits. And that I think is really important. So in vivo editing big. Now, the other thing that's cropped up in recent times is we've just been focused on DNA, but now there's RNA editing, there's epigenetic or epigenomic editing. What are your thoughts about that?Jennifer Doudna (13:26):Very exciting as well. It's kind of a parallel strategy. The idea there would be to, rather than making a permanent change in the DNA of a cell, you could change just the genetic output of the cell and or even make a change to DNA that would alter its ability to be expressed and to produce proteins in the cell. So these are strategies that are accessible, again, using CRISPR tools. And the question is now how to use them in ways that will be therapeutically beneficial. Again, topics that are under very active investigation in both academic labs and at companies.Eric Topol (14:13):Yeah. Now speaking of that, this whole idea of rejuvenation, this is Altos. You may I'm sure know my friend here, Juan Carlos Belmonte, who's been pushing on this for some time at Altos now formerly at Salk. And I know you helped advise Altos, but this idea of basically epigenetic, well using the four Yamanaka factors and basically getting cells that go to a state that are rejuvenated and all these animal models that show that it really happens, are you thinking that really could become a therapy in the times ahead in patients for aging or particular ideas that you have of how to use that?Jennifer Doudna (15:02):Well, you mentioned the company Altos. I mean, Altos and a number of other groups are actively investigating this. Not I would say specifically regarding genome editing, although being able to monitor and probably change gene functions that might affect the aging process could be attractive in the future. I think the hard question there is which genes do we tweak and how do we make sure that it's safe? And better than me I mean, that's a very difficult thing to study clinically because it takes time for one thing, and we probably don't have the best models either. So I think there are challenges there for sure. But along the way, I feel very excited about the kind of fundamental knowledge that will come from those studies. And in particular, this question of how tissues rejuvenate I think is absolutely fascinating. And some organisms do this better than others. And so, understanding how that works in organisms that are able to say regrow a limb, I think can be very interesting.Eric Topol (16:10):And that gets me to that recent study. Well, as you well know, there's a company Verve that's working on the familial hypercholesterolemia and using editing with the PCSK9 through the liver and having some initial, at least a dozen patients have been treated. But then this epigenetic study of editing in mice for PCSK9 also showed results. Of course, that's much further behind actually treating patients with base editing. But it's really intriguing that you can do some of these things without having to go through DNA isn't it?Jennifer Doudna (16:51):Amazing, right? Yeah, it's very interesting.Reducing the Cost of Genome EditingEric Topol (16:54):Wild. Now, one of the things of course that people bring up is, well, this is so darn expensive and it's great. It's a science triumph, but then who can get these treatments? And recently in January, you announced a Danaher-IGI Beacon, and maybe you can tell us a bit about that, because again, here's a chance to really markedly reduce the cost, right?Jennifer Doudna (17:25):That's right. That's the vision there. And huge kudos to my colleague Fyodor Urnov, who really spearheaded that effort and leads the team on the IGI side. But the vision there was to partner with a company that has the ability to manufacture molecules in ways that are very, very hard, of course, for academic labs and even for most companies to do. And so the idea was to bring together the best of genome editing technology, the best of clinical medicine, especially focused on rare human diseases. And this is with our partners at UCSF and with the folks in the Danaher team who are experts at downstream issues of manufacturing. And so the hope there is that we can bring those pieces together to create ways of using CRISPR that will be cost effective for patients. And frankly, we'll also create a kind of roadmap for how to do this, how to do this more efficiently. And we're kind of building the plane while we're flying it, if you know what I mean. But we're trying to really work creatively with organizations like the FDA to come up with strategies for clinical trials that will maintain safety, but also speed up the timeline.Eric Topol (18:44):And I think it's really exciting. We need that and I'm on the scientific advisory board of Danaher, a new commitment for me. And when Fyodor presented that recently, I said, wow, this is exciting. We haven't really had a path to how to get these therapies down to a much lower cost. Now, another thing that's exciting that you're involved in, which I think crosses the whole genome editing, the two most important things that I've seen in my lifetime are genome editing and AI, and they also work together. So maybe before we get into AI for drug discovery, how does AI come into play when you're thinking about doing genome editing?Jennifer Doudna (19:34):Well, the thing about CRISPR is that as a tool, it's powerful not only as a one and done kind of an approach, but it's also very powerful genomically, meaning that you can make large libraries of these guide RNAs that allow interrogation of many genes at once. And so that's great on the one hand, but it's also daunting because it generates large collections of data that are difficult to manually inspect. And in some cases, I believe really very, very difficult to analyze in traditional ways. But imagine that we have ways of training models that can look at genetic intersections, ways that genes might be affecting the behavior of not only other genes, but also how a person responds to drugs, how a person responds to their environment and allows us to make predictions about genetic outcomes based on that information. I think that's extremely exciting, and I definitely think that over the next few years we'll see that kind of analysis coming online more and more.Eric Topol (20:45):Yeah, the convergence, I think is going to be, it's already being done now, but it's just going to keep building. Now, Demis Hassabis, who one of the brilliant people in the field of AI leads the whole Google Deep Mind AI efforts now, but he formed after AlphaFold2 behaving to predict proteins, 200 million proteins of the universe. He started a company Isomorphic Labs as a way to accelerate using AI drug discovery. What can you tell us about that?Jennifer Doudna (21:23):It's exciting, isn't it? I'm on the SAB for that company, and I think it's very interesting to see their approach to drug discovery. It's different from what I've been familiar with at other companies because they're really taking a computational lens to this challenge. The idea there is can we actually predict things like the way a small molecule might interact with a particular protein or even how it might interact with a large protein complex. And increasingly because of AlphaFold and programs like that, that allow accurate prediction of structures, it's possible to do that kind of work extremely quickly. A lot of it can be done in silico rather than in the laboratory. And when you do get around to doing experiments in the lab, you can get away with many fewer experiments because you know the right ones to do. Now, will this actually accelerate the rate at which we get to approved therapeutics? I wonder about your opinion about that. I remain unsure.Editing Out Alzheimer's Risk AllelesEric Topol (22:32):Yeah. I mean, we have one great success story so far during the pandemic Baricitinib, a drug that repurposed here, a drug that was for rheumatoid arthritis, found by data mining that have a high prospects for Covid and now saves lives in Covid. So at least that's one down, but we got a lot more here too. But it, it's great that Demis recruited you on the SAB for Isomorphic because it brings in a great mind in a different field. And it goes back to one of the things you mentioned earlier is how can we get some of this genome editing into a pill someday? Wow. Now, one of the things that for personal interest, as an APOE4 carrier, I'm looking to you to fix my APOE4 and give me APOE2. How can I expect to get that done in the near future?Jennifer Doudna (23:30):Oh boy. Okay, we'll have to roll up our sleeves on that one. But it is appealing, isn't it? I think about it too. It's a fascinating idea. Could we get to a point someday where we can use genome editing as a prophylactic, not as a treatment after the fact, but as a way to actually protect ourselves from disease? And the APOE4 example is a really interesting one because there's really good evidence that by changing the type of allele that one has for the APOE gene, you can actually affect a person's likelihood of developing Alzheimer's in later life. But how do we get there? I think one thing to point out is that right now doing genome editing in the brain is, well, it's hard. I mean, it's very hard.Eric Topol (24:18):It a little bit's been done in cerebral spinal fluid to show that you can get the APOE2 switch. But I don't know that I want to sign up for an LP to have that done.Jennifer Doudna (24:30):Not quite yet.Eric Topol (24:31):But someday it's wild. It's totally wild. And that actually gets me back to that program for coronary heart disease and heart attacks, because when you're treating people with familial hypercholesterolemia, this extreme phenotype. Someday and this goes for many of these rare diseases that you and others are working on, it can have much broader applicability if you have a one-off treatment to prevent coronary disease and heart attacks and you might use that for people well beyond those who have an LDL cholesterol that are in the thousands. So that's what I think a lot of people don't realize that this editing potential isn't just for these monogenic and rare diseases. So we just wanted to emphasize that. Well, this has been a kind of wild ride through so much going on in this field. I mean, it is extraordinary. What am I missing that you're excited about?Jennifer Doudna (25:32):Well, we didn't talk about the microbiome. I'll just very briefly mention that one of our latest initiatives at the IGI is editing the microbiome. And you probably know there are more and more connections that are being made between our microbiome and all kinds of health and disease states. So we think that being able to manipulate the microbiome precisely is going to open up another whole opportunity to impact our health.Can Editing Slow the Aging Process?Eric Topol (26:03):Yeah, I should have realized that when I only mentioned two layers of biology, there's another one that's active. Extraordinary, just going back to aging for a second today, there was a really interesting paper from Irv Weissman Stanford, who I'm sure you know and colleagues, where they basically depleted the myeloid stem cells in aged mice. And they rejuvenated the immune system. I mean, it really brought it back to life as a young malice. Now, there probably are ways to do that with editing without having to deplete stem cells. And the thought about other ways to approach the aging process now that we're learning so much about science and about the immune system, which is one of the most complex ones to work in. Do you have ideas about that are already out there that we could influence the aging process, especially for those of us who are getting old?Jennifer Doudna (27:07):We're all on that path, Eric. Well, I guess the way that I think about it is I like to think that genome editing is going to pave the way to make those kinds of fundamental discoveries. I still feel that there's a lot of our genetics that we don't understand. And so, by being able to manipulate genes precisely and increasingly to look at how genes interact with each other, I think one fundamental question it relates to aging actually is why do some of us age at a seemingly faster pace than others? And it must have to do at least in part with our genetic makeup and how we respond to our environment. So I definitely think there are big opportunities there, really in fundamental research initially, but maybe later to actually change those kinds of things.Eric Topol (28:03):Yeah, I'm very impressed in recent times how much the advances are being made at basic science level and experimental models. A lot of promise there. Now, is there anything about this field that you worry about that keeps you up at night that you think, besides, we talked about that we got to get the cost down, we have to bridge health inequities for sure, but is there anything else that you're concerned about right now?Jennifer Doudna (28:33):Well, I think anytime a new technology goes into clinical trials, you worry that things may get out ahead of their skis, and there may be some overreach that happens. I think we haven't really seen that so far in the CRISPR field, which is great. But I guess I remain cautious. I think that we all saw what happened in the field of gene therapy now decades ago, but that really put a poll on that field for a long time. And so, I definitely think that we need to continue to be very cautious as gene editing continues to advance.Eric Topol (29:10):Yeah, no question. I think the momentum now is getting past that point where you would be concerned about known unknowns, if you will, things that going back to the days of the Gelsinger crisis. But it's really extraordinary. I am so thrilled to have this conversation with you and to get a chance to review where the field is and where it's going. I mean, it's exploding with promise and potential well beyond and faster. I mean, it takes a drug 17 years, and you've already gotten this into two treatments. I mean, I'm struck when you were working on this, how you could have thought that within a 10-year time span you'd already have FDA approvals. It's extraordinary.Jennifer Doudna (30:09):Yeah, we hardly dared hope. Of course, we're all thrilled that it went that fast, but I think it would've been hard to imagine it at the time.Eric Topol (30:17):Yeah. Well, when that gets simplified and doesn't require hospitalizations and bone marrow, and then you'll know you're off to the races. But look, what a great start. Phenomenal. So congratulations. I'm so thrilled to have the chance to have this conversation. And obviously we're all going to be following your work because what a beacon of science and progress and changing medicine. So thanks and give my best to my friend there at IGI, Fyodor, who's a character. He's a real character. I love the guy, and he's a good friend.Jennifer Doudna (30:55):I certainly will Eric, and thank you so much. It's been great talking with you.*******************************************************Thanks for listening and/or reading this edition of Ground Truths.I hope you found it as stimulating as I did. Please share if you did!A reminder that all Ground Truths posts (newsletter and podcast( are free without ads. Soon we'll set it up so you can select what type of posts you want to be notified about.If you wish to be a paid subscriber, know that all proceeds are donated to Scripps Research, and thanks for that—it greatly helped fund our summer internship program for 2023 and 2024.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio/video support. Get full access to Ground Truths at erictopol.substack.com/subscribe

The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don't. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits.Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Earlier this year the Innovative Genomics Institute and the life sciences tools conglomerate Danaher launched a collaborative center to develop genome-editing therapies for rare and other diseases. The Danaher-IGI Beacon for CRISPR Cures seeks to address hundreds of diseases with a unified research, development, and regulatory approach. Their goal is to create a new model for the development of genomic medicines. We spoke to Fyodor Urnov, IGI's director of technology and translation and director of the new Beacon center, about the evolution of gene editing technology, the challenges of a platform approach, and how the organization plans to share what it learns.

In this episode, we're joined by Andrew Brewer to give us some value from his real estate investing adventure, from investing in single-family out-of-state to redevelopment and commercial projects. We'll also cover some of the steps he took to level up his real estate career, the value of having a supportive life partner in business, and the continuous expansion of his company across multiple asset classes. Tune in and never miss this episode!Key Points & Relevant TopicsAndrew's background and his start in real estate navigating different asset classesWhy Andrew decided to invest out of California and choose the Kansas market insteadChallenges of operating and managing properties out-of-stateThe significance of having a support system in real estate investingBuilding a team and partnerships in starting a real estate development businessValuable market insights on Austin and San Antonio, TXThe impact of real estate investing on one's freedom and personal relationshipsResources & LinksApartment Syndication Due Diligence Checklist for Passive InvestorAbout Andrew BrewerAndrew Brewer is a commercial operator and developer who brings years of experience in many facets of real estate to IronGall Investments. He is also the co-founder of Distance 3 Development, a San Antonio-based real estate development and investment firm. Prior to starting IronGall Investments, Andrew had a successful career as a stationary engineer. As an engineer Andrew oversaw operations in high-rise commercial facilities valued individually at over $200M. He successfully completed full building turnarounds of underperforming commercial assets leading to improved operations, lower maintenance costs, and improved resident experiences. In addition to his engineering work, Andrew has acted as a consultant in construction defect litigation lawsuits. He has assisted prosecutors in pursuing judgements in excess of $60M, and overseen commercial reconstruction projects valued individually at over $12m. Andrew formed IronGall Investments in 2017. Backed by Andrew's experience in commercial asset management, construction defect litigation, and commercial reconstruction, IronGall Investments began to sponsor and develop multifamily, townhome, and single-family home communities. Since 2017, IGI has served as the lead sponsor and lead developer on multiple ground up development projects and land subdivision projects comprising hundreds of residential units valued at over 160 million combined. Andrew works tirelessly to keep all of IronGall Investments's projects running smoothly and rigorously evaluates all potential opportunities using IronGall Investments's landmark “Systematic Selection” approach to project evaluation which includes a nuanced analysis of the strengths and weaknesses of each particular project and corresponding market. Get in Touch with AndrewWebsite: IronGall Investments / Distance 3 DevelopmentFacebook: Andrew Brewer / IronGall InvestmentsLinkedIn: Andrew Brewer / IronGall InvestmentsTo Connect With UsPlease visit our website www.bonavestcapital.com and click here to leave a rating and written review!